This is a research study to evaluate the usability of the Cogito digital therapeutics development platform.
The Cogito platform is designed to allow researchers who are seeking to embed an evidence-based behavioral therapy into a digital delivery platform to do so via a drag and drop interface with no programming skills necessary. It will provide the components for building a digital therapeutic for any health condition and population.
And in this initial study, the research team plans to examine the usability of Cogito in building a digital therapeutic for substance use disorders (SUDs).
At least 18 years
PhD and/or MD-level (or equivalent) scientists at academic institutions or digital health companies at the level of Post-doctoral Fellow or higher.
Training or trained in substance use disorder (SUDs) research.
Must state a specific interest in digital therapeutics for SUDs.
Those who do not meet inclusion criteria.
The research team will recruit 20 (\> 18 years) clinical researchers/clinicians to utilize Cogito to provide feedback on its usability, utility, and likability and relevance as a development and hosting platform. Participants must be PhD and/or MD-level scientists at academic institutions or digital health companies at the level of Post-doctoral Fellow or higher. Participants must be trained/training in SUD research. Participants must state a specific interest in digital therapeutics for SUDs. The researchers expect participants will have interests ranging from developing novel behavioral digital therapies for SUDs to digital therapeutics that promote adherence to SUD medications to digital therapeutics for SUDs and co-occurring conditions to digital management tools which help individuals with care transitions.
Other
Prospective
Cogito digital therapeutics development platform
Other interventionCogito will provide a turnkey solution for rapidly developing, evaluating, deploying, and scaling digital therapeutics for the prevention, treatment and/or management of any disease or disorder. This platform will allow researchers who are seeking to embed an evidence-based behavioral therapy into a digital delivery platform to do so via a drag and drop interface with no programming skills necessary. It will provide all the components for building a digital therapeutic for any health condition and population. Overall, Cogito offers great promise to markedly accelerate the pace and impact of science based digital therapeutics.
System Usability Scale
Each participant will be asked to complete the standardized 10-item System Usability Scale (SUS) to evaluate the usability of Cogito (e.g., "I think I would like to use this system frequently"), ranging from "strongly agree" to "strongly disagree".
Visual Analog Scales
100 mm Visual Analog measures, ranging from "Not at All" anchored at 0 to "Very" anchored at 100 for each question, with every question worded positively to assess how (1) easy to use, (2) understandable, (3) likable, (4) useful (5) relevant they found the Cogito development functionality in each stage of the scavenger hunt as well as (6) how likely they would be to use Cogito as a digital therapeutics development and hosting platform.
Click on the lead sponsor to view all of their trials.
Square2 Systems, Inc.
Lead sponsor
National Institute on Drug Abuse (NIDA)
Collaborator
